AbbVie (ABBV) vs. Eli Lilly (LLY): Insights for 2026 Investors
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowIn FY 2025, AbbVie Inc (NYSE:ABBV) reported revenue of nearly $61.2 billion, growing 8.7% from the previous year, with net income around $4.3 billion. Eli Lilly and Co (NYSE:LLY) achieved revenue of approximately $65.2 billion, a significant increase of 45% year-over-year, and net income around $20.6 billion. AbbVie's revenue is heavily reliant on Skyrizi and Rinvoq, while Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, significantly contribute to its growth. Investors should note the differing risk profiles, with AbbVie facing patent expiration pressures and price reductions affecting certain products, which may influence investment choices.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About AbbVie Inc. (ABBV)
AbbVie is a research-based pharmaceutical company with a portfolio spanning immunology, oncology, and neuroscience.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ABBV news
- Altria (MO), Chevron (CVX): 4% Yield Dividend Stocks Insight
- AbbVie (ABBV) Presents Lung Cancer Data at WCLC 2026 Conference
- AbbVie Expects $12.7 Billion in Neuroscience Sales This Year
- AbbVie (ABBV) Stock Declines Amid Market Uncertainty
- AbbVie (ABBV) Trims 2026 Profit Forecast Following Apogee Acquisition
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
